Ferinject, or intravenous ferric carboxymaltose, met the main goal of a clinical trial by significantly reducing the use of erythropoiesis-stimulating agents and transfusions among patients with non-dialysis-dependent chronic kidney disease. More than 600 patients participated in the international, 56-week study. They received either oral iron or 1,000 milligrams of ferric carboxymaltose initially and more as needed.

Full Story:
PharmaTimes (U.K.)

Related Summaries